Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Wednesday, October 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab Limited announced that it will present data from its first clinical trial of ZL-1503, a bispecific antibody targeting IL-13 and IL-31Rα, at the ACAAI 2026 Annual Scientific Meeting. This meeting is scheduled for November 12-16, 2026, in Phoenix, AZ. The trial focuses on atopic diseases, showcasing Zai Lab's commitment to innovative therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zai Lab is advancing its innovative bispecific antibody ZL-1503.
  • The data presentation at a major scientific meeting highlights the company's research efforts.
  • Potential treatment for atopic diseases could significantly impact patient care.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~27 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company’s internally developed interleukin-13 (IL-13) and interleukin-31 (IL-31)Rα bispecific antibody, will be shared for the first time at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in Phoenix, AZ. “Atopic dermatitis and other IL-13- and I

Frequently Asked Questions

What is ZL-1503?

ZL-1503 is a bispecific antibody developed by Zai Lab targeting IL-13 and IL-31Rα.

When will Zai Lab present the ZL-1503 data?

The data will be presented at the ACAAI 2026 Annual Scientific Meeting from November 12-16, 2026.

What diseases does ZL-1503 aim to treat?

ZL-1503 is aimed at treating atopic diseases, including atopic dermatitis.

Where is the ACAAI 2026 meeting taking place?

The ACAAI 2026 Annual Scientific Meeting will be held in Phoenix, AZ.

ShareAdd on Google
Tags: ZLAB Zai Lab ZL-1503 clinical trial atopic diseases ACAAI 2026
Last updated: Oct 14, 2026

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~27 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+60%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →